AYA.AX Artrya Limited ASX falls 5.04% to A$3.20 intraday: AI diagnosis growth under watch

Artrya Limited (AYA.AX) is trading A$3.20 intraday on the ASX, down 5.04% on volume of 274,842 shares. The move follows mixed trading since the open at A$3.35, with a day low of A$3.12 and a day high of A$3.35. We track AYA.AX stock as part of the AI healthcare cohort. This note uses real-time quote details, sector context and Meyka AI-powered market analysis platform signals to assess near-term catalysts and upside targets for investors in Australia (AUD) markets.

AYA.AX stock intraday price action

AYA.AX stock is at A$3.20, down A$0.17 from the prior close of A$3.37. Trading range today is A$3.12–A$3.35 and volume is 274,842, below the 30-day average volume of 566,777. The session open was A$3.35, showing sellers stepped in early. One clear claim: short-term liquidity is light, so intraday moves can amplify on news or order flow.

We link company filings and investor pages for verification: Artrya website and the company quote on the ASX site for trade confirmations ASX – AYA.

AYA.AX stock valuation and fundamentals

Artrya reports EPS -A$0.17 and a negative price/earnings metric of -18.82. Market capitalisation is A$364,160,000.00 with 113,800,000 shares outstanding. The company shows substantial R&D focus at 84.34% of revenue and cash per share of A$0.61. Book value per share is A$0.71 and price-to-book sits at 4.50.

Claim: fundamentals reflect an early-stage AI healthcare model with high R&D intensity and limited revenue per share (A$0.00 rounded). Investors must weigh growth potential against negative margins and high valuation multiples.

AYA.AX stock technicals and short-term indicators

Technical indicators are mixed. RSI is 46.38 and MACD histogram is 0.05, suggesting neutral momentum. The 50-day average price is A$3.67 and the 200-day average is A$2.65. Bollinger Bands middle is A$3.21 with an upper band at A$3.49 and lower at A$2.93.

Claim: price sits below the 50-day mean, which acts as immediate resistance at around A$3.67. Support lies near the recent low A$3.12 and the long-term floor at the 52-week low A$0.56.

Meyka AI rates AYA.AX stock with a score out of 100

Meyka AI rates AYA.AX with a score out of 100. The proprietary score is 63.44 (Grade B) and the suggestion is HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade balances strong cash buffers against persistent losses and high R&D spend.

Important: These grades are model outputs. These grades are not guaranteed and we are not financial advisors.

AYA.AX stock forecast and price target

Meyka AI’s forecast model projects monthly A$3.05, quarterly A$4.36, and yearly A$7.41. Versus the current A$3.20, implied moves are: monthly -4.69%, quarterly +36.25%, yearly +131.47%. Our near-term realistic price target is A$4.36 for the next quarter and A$7.41 for 12 months, conditional on commercial uptake of Salix and revenue ramps.

Forecasts are model-based projections and not guarantees. They assume steady AI adoption in coronary imaging and no major capital dilution.

AYA.AX stock risks and opportunities in AI healthcare

Opportunity: Artrya’s Salix platform targets automated coronary disease detection. If adoption accelerates, revenue per customer could rise quickly. The company has low leverage with debt to equity near 0.01, which supports runway for expansion.

Risk: healthcare AI adoption faces regulatory reviews, payer approval cycles and slow sales cycles. Trading liquidity is modest; average volume 566,777 can lead to sharp intraday swings. Sector context: the Australian healthcare sector is down 10.12% YTD, increasing macro headwinds for small innovators.

Final Thoughts

Key takeaway: AYA.AX stock is trading at A$3.20 intraday after a 5.04% decline. Valuation shows high R&D investment, negative earnings and modest cash per share. Meyka AI’s forecast model projects a quarterly target A$4.36 (+36.25%) and a 12-month target A$7.41 (+131.47%) versus the current price. We assign weight to the company’s AI product traction, low debt and cash runway. Offsetting this, losses and regulatory timing create real execution risk. For traders, watch resistance near the A$3.67 50-day average and support at A$3.12. For investors, monitor commercial metrics: customer sign-ups, recurring revenue growth and regulatory milestones. These projections are model-based and not guarantees. For more detail and live updates visit our Meyka AI stock page for AYA.AX and company filings on the ASX.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.